NAMenclature

#

New Approach Methodologies (NAM) represent a paradigm shift in biomedical research, toxicology, and regulatory science. By replacing or reducing reliance on animal testing, NAM leverages cutting-edge technologies to generate human-relevant data, improve predictive accuracy, and align with modern ethical and scientific standards. This document introduces six key NAM technologies, organized to highlight their historical progression, technological appeal, and real-world impact.

Item	Description	Application
In Chemico	Non-biological chemical testing methods using synthetic systems (e.g., peptides, proteins) to assess reactivity.	Replaces animal tests such as Draize, Guinea Pig Maximization Test (GPMT), and phototoxicity tests. Modernized through High-Throughput Screening (HTS).
In Silico	Computational methods, including modeling and simulations, to predict biological outcomes.	Used for PBPK modeling and AI/ML-driven drug discovery, with higher predictive accuracy and lower cost compared to animal models.
In Vitro	Laboratory-based methods using human-derived cells or tissues, including organoids (3D cell cultures) and organ-on-a-chip systems.	Mimics human physiology for drug testing, disease modeling, and personalized medicine.
Bioprinting	3D printing technology adapted to create complex, functional human tissue structures using bioinks.	Tissue engineering, drug testing, and regenerative medicine.
Omics	Systems-level approaches that analyze large datasets of biological molecules, including genomics, proteomics, and metabolomics.	Enables systems biology framework and personalized medicine, including digital twin concepts.
AOPs	Frameworks that link molecular-level data to adverse health outcomes through defined pathways.	Supports regulatory decision-making by connecting mechanistic insights to real-world toxicological effects.

Strategic Callouts

#

For Scientists

#

Produce Human-Relevant Data - Because Science Should Work for Humans, Not Animals

New Approach Methodologies (NAM) enable you to generate human-predictive data that animal models cannot. By adopting In Silico (PBPK modeling, AI/ML), In Vitro (organoids, organ-on-a-chip), and Omics technologies, you eliminate species-specific biases, reduce false leads, and accelerate breakthroughs. In Chemico methods replace outdated animal tests (e.g., Draize, GPMT), while Bioprinting and Adverse Outcome Pathways (AOPs) provide next-generation tools for drug development and regulatory decision-making. Laboratories embracing NAM gain a competitive edge, attract modern funding, and align with the global shift toward precision medicine. The future is human-focused biomedical innovation - are you leading the charge or being left behind?

For Educators

#

Equip Students for the Biotech Revolution - Not the Textbooks of Yesterday

Animal dissection and outdated toxicological assays teach obsolete skills for a world that has moved on. Today’s biotechnology demands expertise in In Silico (AI/ML, PBPK modeling), In Vitro (organoids, organ-on-a-chip), and Omics (genomics, proteomics). By integrating NAM into your curriculum, you prepare students for careers where human-relevant methods drive discovery, reduce costs, and align with industry needs. Bioprinting and AOPs offer tangible, cutting-edge applications to inspire the next generation of scientists. The question isn’t if you should modernize your teaching - it’s how soon you can start.

For Policymakers

#

Modernize or Risk Falling Behind: Canada’s Scientific and Economic Future Is at Stake

While the U.S. (FDA Modernization Act 2.0)¹ and E.U. actively fund and legislate the phase-out of animal models, Canada’s regulatory frameworks remain dangerously stagnant. In Chemico and In Silico methods (PBPK, AI/ML) already replace animal tests with faster, cheaper, and more accurate alternatives. In Vitro (organoids, organ-on-a-chip), Bioprinting, and Omics technologies are revolutionizing drug development and toxicology. Adverse Outcome Pathways (AOPs) provide the scientific rigor regulators demand. Modernizing public funding to mandate NAM infrastructure is not just a scientific imperative - it’s a matter of national economic survival.

Frequently Asked Questions

#

In Chemico

#

How does In Chemico testing replace traditional animal tests like the Draize test?

#

In Chemico methods, such as the Direct Peptide Reactivity Assay (DPRA), assess chemical reactivity using synthetic peptides, eliminating the need for animal subjects. This approach is faster, more cost-effective, and ethically superior to traditional tests like the Draize test or Guinea Pig Maximization Test (GPMT). Modernization through High-Throughput Screening (HTS) has further automated and scaled these methods, enabling rapid assessment of thousands of chemicals.

What are the advantages of In Chemico over animal testing?

#

In Chemico methods provide consistent, reproducible results without the ethical concerns or biological variability associated with animal testing. They are particularly effective for assessing skin sensitization and phototoxicity, where chemical reactivity is the primary concern. Additionally, HTS enables researchers to screen large chemical libraries efficiently, accelerating the identification of safe and effective compounds².

In Silico

#

How do PBPK modeling and AI/ML improve drug discovery?

#

Physiologically Based Pharmacokinetic (PBPK) modeling simulates how drugs are absorbed, distributed, metabolized, and excreted in the human body, providing predictive insights into drug behavior without animal testing. AI/ML enhances this process by analyzing vast datasets to identify patterns and predict outcomes, significantly improving the accuracy and efficiency of drug discovery. These methods reduce reliance on animal models, which often fail to predict human responses due to species differences³.

Why are In Silico methods more predictive than animal models?

#

In Silico methods leverage human-specific data and computational power to model biological processes directly relevant to humans. Unlike animal models, which can produce misleading results due to inter-species differences, In Silico approaches are designed to reflect human physiology, leading to higher translational success rates. For example, PBPK modeling has been shown to predict drug metabolism and toxicity in humans with greater accuracy than animal tests, while AI-driven models can identify potential drug candidates or toxicities at unprecedented speeds⁴.

What cost savings are associated with In Silico methods compared to animal testing?

#

In Silico methods, such as PBPK modeling and AI/ML-driven drug discovery, offer substantial cost savings compared to traditional animal testing. For instance, the average cost of bringing a drug to market is estimated at over $2.6 billion, with a significant portion attributed to animal testing and failed clinical trials due to poor animal-to-human translation. In Silico methods reduce these costs by streamlining the drug development pipeline, minimizing false leads, and improving the predictive accuracy of preclinical research. For more details, refer to our report on drug development costs.

In Vitro

#

How do organoids differ from traditional 2D cell cultures?

#

Organoids are 3D cell cultures that mimic the structure and function of human organs, providing a more physiologically relevant model than traditional 2D cultures. While 2D cultures lack the complex interactions and architecture of human tissues, organoids recapitulate tissue-specific microenvironments, enabling more accurate studies of disease mechanisms, drug responses, and developmental processes.

Caption: A comparison of organoid (3D) and traditional 2D cell cultures, highlighting the structural and functional advantages of organoids.

What are the applications of organ-on-a-chip technology?

#

Organ-on-a-chip (OOAC) systems are microfluidic devices that replicate the physiological functions of human organs, such as the liver, heart, or lungs. These systems enable researchers to study disease mechanisms, drug metabolism, and toxicology in a controlled, human-relevant environment. Applications include drug testing, personalized medicine, and disease modeling, with the potential to replace animal models in preclinical research.

Caption: A schematic of an organ-on-a-chip device, illustrating its ability to mimic human organ function.

Bioprinting

#

How is bioprinting related to 3D printing?

#

Bioprinting is a specialized form of 3D printing that uses bioinks - mixtures of cells and hydrogels - to construct functional human tissue structures. While traditional 3D printing creates objects from materials like plastic or metal, bioprinting builds living tissues layer by layer, enabling the creation of complex, human-like models for research and medical applications.

What are the key applications of bioprinting in biomedical research?

#

Bioprinting is revolutionizing biomedical research by enabling the creation of tissue models for drug testing, disease modeling, and regenerative medicine. For example, bioprinted liver tissues can be used to study drug metabolism and toxicity, while bioprinted skin models can replace animal testing for cosmetic and chemical safety assessments. Additionally, bioprinting holds promise for organ transplantation, with ongoing research into printing functional organs for clinical use.

Caption: The bioprinting process, showing how bioinks are used to create layered, functional human tissues.

Omics

#

What are the main components of Omics technologies?

#

Omics technologies include genomics (study of DNA), transcriptomics (study of RNA), proteomics (study of proteins), and metabolomics (study of metabolites). Each component provides a systems-level understanding of biological processes, enabling researchers to analyze the complex interactions that drive health and disease.

How does Omics enable systems biology and personalized medicine?

#

Omics technologies provide a holistic view of biological systems, allowing researchers to identify biomarkers, understand disease mechanisms, and develop targeted therapies. For example, genomics can reveal genetic mutations linked to diseases, while proteomics can identify protein targets for drug development. This systems-level approach is the foundation of personalized medicine, where treatments are tailored to an individual’s unique biological profile. Omics also enables the development of digital twins - virtual models of a patient’s physiology that can be used to simulate and optimize treatments⁵.

Adverse Outcome Pathways (AOPs)

#

How do Adverse Outcome Pathways link molecular data to regulatory decisions?

#

Adverse Outcome Pathways (AOPs) are scientific frameworks that connect molecular-level events (e.g., a chemical binding to a receptor) to adverse health outcomes (e.g., liver toxicity) through a series of biologically plausible steps. AOPs provide a transparent, evidence-based approach to assessing chemical safety, enabling regulators to make informed decisions without relying on animal testing. By integrating data from In Chemico, In Silico, and In Vitro methods, AOPs offer a comprehensive understanding of how chemicals affect human health.

Can you provide an example of a successful AOP case study?

#

One notable example is the AOP for skin sensitization, which links chemical reactivity (measured via In Chemico methods like DPRA) to allergic contact dermatitis. This AOP has been widely adopted by regulatory agencies, including the OECD, as a non-animal alternative for assessing the skin sensitization potential of chemicals. By using AOPs, regulators can evaluate chemical safety with greater confidence and human relevance than traditional animal tests⁶.

Can I print this document?

#

This Talking Point is available for download right here.

References

#